Literature DB >> 15273715

Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer.

Milo Frattini1, Cristina Ferrario, Paola Bressan, Debora Balestra, Loris De Cecco, Piera Mondellini, Italia Bongarzone, Paola Collini, Manuela Gariboldi, Silvana Pilotti, Marco A Pierotti, Angela Greco.   

Abstract

Papillary thyroid carcinoma (PTC) is associated with RET and NTRK1 rearrangements and BRAF mutations. A series of 60 PTCs collected in a single center from Italian patients were histologically re-examined and subclassified as well differentiated or tall cell variant. The sample collection was analysed for the presence of all the reported PTC-associated genetic alterations through DNA or cDNA amplification, followed by automated sequencing. The analysis of exons 11 and 15 of BRAF gene revealed the T1796A (V599E) mutation in 32% of cases, and this alteration is significantly associated with PTC tall cell variant. Oncogenic rearrangements of RET and NTRK1 receptors were found in 33 and 5% of cases, respectively. No Ras mutations were detected. Overall, genetic alterations were detected in two-thirds of samples, and in no single case more than one mutational event was found simultaneously. Gene expression profiling of a subset of 31 tumors performed using cDNA microarray chips showed no strong differences in global gene expression among the different cases. However, a supervised analysis of the obtained data identified a subset of genes differentially expressed in tumors carrying BRAF mutation or RTK rearrangement.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15273715     DOI: 10.1038/sj.onc.1207980

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  80 in total

1.  Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer.

Authors:  Jie Ming; Zeming Liu; Wen Zeng; Yusufu Maimaiti; Yawen Guo; Xiu Nie; Chen Chen; Xiangwang Zhao; Lan Shi; Chunping Liu; Tao Huang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

2.  Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene.

Authors:  Maria Grazia Borrello; Luisella Alberti; Andrew Fischer; Debora Degl'innocenti; Cristina Ferrario; Manuela Gariboldi; Federica Marchesi; Paola Allavena; Angela Greco; Paola Collini; Silvana Pilotti; Giuliana Cassinelli; Paola Bressan; Laura Fugazzola; Alberto Mantovani; Marco A Pierotti
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

Review 3.  Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis.

Authors:  Leslie R Rowe; Brandon G Bentz; Joel S Bentz
Journal:  J Clin Pathol       Date:  2007-02-13       Impact factor: 3.411

Review 4.  Molecular pathology of thyroid cancer: diagnostic and clinical implications.

Authors:  James A Fagin; Nicholas Mitsiades
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-12       Impact factor: 4.690

5.  Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis.

Authors:  Gisele Oler; Cléber P Camacho; Flávio C Hojaij; Pedro Michaluart; Gregory J Riggins; Janete M Cerutti
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

6.  Multifocal fibrosing thyroiditis and its association with papillary thyroid carcinoma using BRAF pyrosequencing.

Authors:  Renee Frank; Zubair W Baloch; Caren Gentile; Christopher D Watt; Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2014-09       Impact factor: 3.943

7.  Identification of a novel HRAS variant and its association with papillary thyroid carcinoma.

Authors:  Rui Dou; Lili Zhang; Tingxia Lu; Dong Liu; Fang Mei; Jian Huang; Linxue Qian
Journal:  Oncol Lett       Date:  2018-01-17       Impact factor: 2.967

8.  Clinical significance of mannose-binding lectin expression in thyroid carcinoma tissues.

Authors:  Yifang Lu; Guogui Sun; Geling Liu; Yanping Shi; Ying Han; Fang Yu; Xiuxiu Xiang; Weijuan Li; Hongzhen Xiao; Xiuling Liu; Sha Li
Journal:  Pathol Oncol Res       Date:  2012-12-19       Impact factor: 3.201

9.  High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma.

Authors:  Ying C Henderson; Thomas D Shellenberger; Michelle D Williams; Adel K El-Naggar; Mitchell J Fredrick; Kathleen M Cieply; Gary L Clayman
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

10.  BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

Authors:  Rebecca Leboeuf; Jacqueline E Baumgartner; Miriam Benezra; Roberta Malaguarnera; David Solit; Christine A Pratilas; Neal Rosen; Jeffrey A Knauf; James A Fagin
Journal:  J Clin Endocrinol Metab       Date:  2008-04-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.